Institute of Cancer Research Confidence in Concept (ICR CiC)
Lead Research Organisation:
Institute of Cancer Research
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Bland P
(2023)
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
in Nature genetics
Caravagna G
(2020)
Subclonal reconstruction of tumors by using machine learning and population genetics.
in Nature genetics
Garancher A
(2020)
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
in Nature neuroscience
George S
(2020)
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
in eBioMedicine
George SL
(2020)
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
in Journal of experimental & clinical cancer research : CR
| Description | CR UK SMPaeds |
| Amount | £2,380,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2023 |
| Description | CwCUK IMPACT |
| Amount | £1,500,000 (GBP) |
| Funding ID | 17-325 |
| Organisation | Children with Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2017 |
| End | 06/2020 |
| Title | Isolation of ALK/MYCN cfDNA for cfDNA testing |
| Description | Protocol for concurrent isolation of paediatric cfDNA and germline DNA from a single DNA-preservation tube at low sample volume <2cc |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | this is a major advance that will allow collection of cfDNA and constitutional DNA from children in volumes <2cc and will be implemented nationally through the CCLG biobank for children in 2016 |
| Title | Next generation sequencing and digital PCR of murine and human tumour and blood samples for ALK, MYCN and additional gene-mutations |
| Description | we have developed both digital PCR and customised capture sequencing panels for detection of MYCN, ALK and other paediatric actionable mutations |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | we have begun clinical testing of patients at Royal Marsden Hospital and nationally through the CCLG tumour bank (using patient tissues from all 9 paediatric ECMC hospitals in the UK) using the NGS panel. |
| Description | Cyclacel CYC065 targeting of MYCN in paediatric cancer |
| Organisation | Cyclacel Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | in vitro and in vivo studies in paediatric cancer, mouse hospital validation |
| Collaborator Contribution | compound and chemical expertise |
| Impact | paper in review, nature - mycn inhibition in neuroblastoma paper in development - mycn inhibition in medulloblastoma clinical trials proposal paediatric phase I study concept planning in progress |
| Start Year | 2010 |
| Description | Cyclacel sponsored phase I/II clinical trial of CYC065 in paediatric solid tumours |
| Organisation | Cyclacel Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | we have through the MRC grant, developed the assays for MYCN copy number that will be used as a biomarker for patient selection/trial enrolment, and for monitoring disease progression in ctDNA. |
| Collaborator Contribution | trial sponsorship, drug distribution, intellectual property. |
| Impact | clinical trial in development |
| Start Year | 2017 |
| Description | ITCC CYC065 inhibitor phase I/II clinical trial |
| Organisation | Innovative Therapies for Children with Cancer (ITCC) Consortium |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | we performed the science that identified the drug and mechanism of targeting of MYCN |
| Collaborator Contribution | industry partner for research, provided compound and pharmacokinetic assays |
| Impact | clinical trial proposal and papers in progress |
| Start Year | 2014 |
| Description | ITCC Clinical phase I trial of ALK inhibitor therapy |
| Organisation | Innovative Therapies for Children with Cancer (ITCC) Consortium |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | we developed the assays for sequencing, and for MYCN, ALK and ROS/MET copy number on tumour tissue through this trial, as well as for digital PCR analysis in ctDNA |
| Collaborator Contribution | financial support for biology assay - trial results confirmation |
| Impact | development of assays for clinical trials and research use |
| Start Year | 2017 |
| Description | ITCC eSMART clinical trial |
| Organisation | Innovative Therapies for Children with Cancer (ITCC) Consortium |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | we are the biomarker testing programme (CRUK-SMPaeds) for the ITCC eSMART trial in the UK |
| Collaborator Contribution | they run the clinical trial and provide clinical materials for testing. they serve as a rapid conduit for clinical validation of our research findings (to identify targeted drugs). |
| Impact | we act as central biology laboratory and as clinical lead site for conduct of this trial |
| Start Year | 2016 |
| Description | Michael Hubank |
| Organisation | Royal Marsden Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Key strategic partner in the molecular profiling and sequencing programmes (co-CIs). Driving the panel sequencing and ddPCR for paediatrics and devising unique platforms, trials and programmes |
| Collaborator Contribution | Driving the panel sequencing and ddPCR for paediatrics and devising unique platforms, trials and programmes |
| Impact | SMPaeds; IMPACT; METEOR; Panel Sequencing; CRISP trial; eSMART trial |
| Start Year | 2017 |
| Description | SIOPEN Neuroblastoma High Risk-2 Clinical Trial |
| Organisation | SIOPEN |
| Country | Austria |
| Sector | Charity/Non Profit |
| PI Contribution | We will be conducting blood-based testing of ctDNA from UK neuroblastoma patients on the upcoming high-risk induction clinical trial (SIOPEN-HR2). |
| Collaborator Contribution | SIOPEN implements these trials through a clinical-academic partnership EU-UK wide. As part of this, biomarker development is collaboratively planned. We will be testing the plasma obtained from frontline patients on treatment, to look for markers of MRD. |
| Impact | no outputs as yet, ahead of planned trial opening in 2020 |
| Start Year | 2019 |
| Title | PARP INHIBITORS FOR USE IN TREATING CANCER |
| Description | The use of poly ADP ribose polymerase (PARP) inhibitors the treatment of cancer which is mutated or deficient in the SF3B gene is described based on findings indicating that mutations in SF3B1aretherapeutically tractable in cancers using PARP inhibitors and show an impaired response to DNA damage. |
| IP Reference | WO2018224536 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | None |
| Title | Clinical Trial - eSMART in paediatric relapsed solid tumours |
| Description | Formal molecular profiling platform for SMPaeds. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2019 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | As above |
| URL | https://clinicaltrials.gov/show/NCT02813135 |
| Description | AACR 2019 Organising Committee |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | organising committee for paediatric oncology AACR |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=174 |
| Description | CCLG Summer Meeting - SMPaeds/IMPACT talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Engagement lecture on upcoming stratified medicine initiative for Paediatrics. Attended predominately by clinicians and sparked significant discussions and questions on the important of molecular profiling of paediatric tumours including requests for further information and centre participation. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Dr Adam Sharp: Targeting aberrant androgen receptor signaling in metastatic castration resistant prostate cancer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Adam Sharp attended the Prostate Cancer UK Clinical Forum. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Dr Adam Sharp: Targeting aberrant androgen receptor signaling in metastatic castration resistant prostate cancer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Drug Development Unit Seminar. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Dr Adam Sharp: triving to be a Clinician-Scientist: The journey so far. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Research Network Day |
| Year(s) Of Engagement Activity | 2010,2017 |
| Description | Dr Adam Sharp:Overcoming aberrant androgen signaling in advanced prostate cancer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Event organised by The Royal Society of Medicine. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Host Meeting - ITCC Biology 2019 London |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | hosted the yearly international meeting of ITCC for biology |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://www.itcc-consortium.org/ |
| Description | SIOPEN Conference - participation and lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lecture aimed at engaging and informing international and European activities linked to our SMPaeds/IMPACT initiative to molecularly profile patients to better assign them to clinical trials. This sparked significant discussions and questions on the important of molecular profiling of paediatric tumours. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk and participation CwCUK Childhood Cancer Conference 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Participated and delivered a lecture on the IMPACT/SMPaeds. The conference was attended predominately by parents and sparked significant discussions and questions on the important of molecular profiling of paediatric tumours. |
| Year(s) Of Engagement Activity | 2017 |